Regeneron Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $1175 to $1077.
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals shares declined following a downgrade by Leerink Partners from Outperform to Market Perform, with a reduced price target from $1175 to $1077.
September 24, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals experienced a share price decline after Leerink Partners downgraded its rating from Outperform to Market Perform and reduced the price target from $1175 to $1077.
The downgrade by Leerink Partners and the reduction in the price target are likely to negatively impact investor sentiment, leading to a short-term decline in Regeneron's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100